Adenosine A2A receptor antagonists as positron emission tomography (PET) tracers

Current Medicinal Chemistry

Volumn 21, Issue 3, 2014, Pages 312-328

  Khanapur, S ^a   Van Waarde, A ^a   Ishiwata, K ^b   Leenders, K L ^a   Dierckx, R A J O ^a,c   Elsinga, P H ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

6 OHDA PD model; Adenosine A2A receptor; Nonxanthine ligands; Parkinson's disorder; Positron emission tomography (PET); SCH442416; TMSX; Xanthine ligands

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; LIGAND; TRACER; XANTHINE;

ARTICLE; CLINICAL STUDY; DRUG DESIGN; DRUG SCREENING; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR DOCKING; MOLECULAR IMAGING; MOLECULAR MODEL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BRAIN; HUMANS; MOLECULAR DOCKING SIMULATION; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ADENOSINE A2A; XANTHINES;

EID: 84893232020     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660265     Document Type: Article

References (118)

1. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. Nomenclature and classification of purinoceptors. Pharmacol. Rev., 1994, 46, 143-156.
2. Hess, S. Recent advances in adenosine receptor antagonist research. Expert Opin. Ther. Patents, 2001, 11, 1533-1561.
3. Ishiwata, K.; Kimura, Y.; De Vries, Erik F. J.; Elsinga, P. H. PET Tracers for Mapping Adenosine Receptors as Probes for Diagnosis of CNS Disorders. Cent. Nerv. Syst. Agents Med. Chem., 2007, 7, 57-77.
4. Palmer, T. M.; Stiles, G. L. Adenosine receptors. Neuropharmacology, 1995, 34, 683-694.
5. Linden, J. Adenosine in Tissue Protection and Tissue Regeneration. Mol. Pharmacol., 2005, 67, 1385-1387.
6. Dunwiddie, T.; Masino, S. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci., 2001, 24, 31-55.
7. von Lubitz, D. K. Adenosine in the treatment of stroke: yes, maybe, or absolutely not? Expert Opin. Investig. Drugs, 2001, 10, 619-632.
8. Ribeiro, J. A.; Sebastião, A. M.; de Mendonça, A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol., 2002, 68, 377-392.
9. Jacobson, K. A.; Gao, Z. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov., 2006, 5, 247-264.
10. El Yacoubi, M.; Costentin, J.; Vaugeois, J. M. Adenosine A2A receptors and depression. Neurology, 2003, 61, S82-S87.
11. Holschbach, M. H.; Olsson, R. A.; Bier, D.; Wutz, W.; Sihver, W.; Schüller, M.; Palm, B.; Coenen, H. H. Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1- propylxanthine ([18F]CPFPX): A Potent and Selective A1- Adenosine Receptor Antagonist for in Vivo Imaging. J. Med. Chem., 2002, 45, 5150-5156.
12. Paul, S.; Elsinga, P. H.; Ishiwata, K.; Dierckx, R. A.; van Waarde, A. Adenosine A(1) receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging. Curr. Med. Chem., 2011, 18, 4820-4835.
13. Sebastião, A. M.; Ribeiro, J. A. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br. J. Pharmacol., 2009, 158, 15-22.
14. Ralevic, V.; Burnstock, G. Receptors for Purines and Pyrimidines. Pharmacol. Rev., 1998, 50, 413-492.
15. Ji, X. D.; Stiles, G. L.; van Galen, P. J.; Jacobson, K. A. Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. J. Recept. Res., 1992, 12, 149-169.
16. Goodman, R. R.; Synder, S. H. Autoradiographic localization of adenosine receptors in rat brain using [3H]cyclohexyladenosine. J. Neurosci., 1982, 2, 1230-1241.
17. Lindstrom, K.; Ongini, E.; Fredholm, B. B. The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol., 1996, 354, 539-541.
18. Ongini, E.; Fredholm, B. B. Pharmacology of adenosine A2A receptors. Trends Pharmacol. Sci., 1996, 17, 364-372.
19. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Linden, J.; Muller, C. E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol. Rev., 2011, 63, 1-34.
20. Moreau, J.; Huber, G. Central adenosine A2A receptors: an overview. Brain Res. Rev., 1999, 31, 65-82.
21. Horstink, M.; Tolosa, E.; Bonuccelli, U.; Deuschl, G.; Friedman, A.; Kanovsky, P.; Larsen, J. P.; Lees, A.; Oertel, W.; Poewe, W.; Rascol, O.; Sampaio, C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur. J. Neurol., 2006, 13, 1186-1202.
22. Horstink, M.; Tolosa, E.; Bonuccelli, U.; Deuschl, G.; Friedman, A.; Kanovsky, P.; Larsen, J. P.; Lees, A.; Oertel, W.; Poewe, W.; Rascol, O.; Sampaio, C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society? European Section. Part I: early (uncomplicated) Parkinson's disease. Eur. J. Neurol., 2006, 13, 1170-1185.
23. Fabbrini, G.; Brotchie, J. M.; Grandas, F.; Nomoto, M.; Goetz, C. G. Levodopa-induced dyskinesias. Mov. Disord., 2007, 22, 1379- 89; quiz 1523.
24. Jankovic, J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord., 2005, 20 Suppl 11, S11-S16.
25. Jankovic, J.; Stacy, M. Medical management of levodopaassociated motor complications in patients with Parkinson's disease. CNS Drugs, 2007, 21, 677-692.
26. Morelli, M.; Carta, A. R.; Jenner, P. Adenosine A2A receptors and Parkinson's disease. Handb. Exp. Pharmacol., 2009, 193, 589-615.
27. Ferre, S.; Karcz-Kubicha, M.; Hope, B. T.; Popoli, P.; Burgueno, J.; Gutierrez, M. A.; Casado, V.; Fuxe, K.; Goldberg, S. R.; Lluis, C.; Franco, R.; Ciruela, F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 11940-11945.
28. Coccurello, R.; Breysse, N.; Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology, 2004, 29, 1451-1461.
29. Schiffmann, S. N.; Fisone, G.; Moresco, R.; Cunha, R. A.; Ferre, S. Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol., 2007, 83, 277-292.
30. Ferré, S.; Goldberg, S. R.; Lluis, C.; Franco, R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology, 2009, 56, Supplement 1, 226-234.
31. Marcellino, D.; Carriba, P.; Filip, M.; Borgkvist, A.; Frankowska, M.; Bellido, I.; Tanganelli, S.; Muller, C. E.; Fisone, G.; Lluis, C.; Agnati, L. F.; Franco, R.; Fuxe, K. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology, 2008, 54, 815-823.
32. Olah, M. E.; Stiles, G. L. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 581-606.
33. Shryock, J. C.; Snowdy, S.; Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Monopoli, A.; Ongini, E.; Baker, S. P.; Belardinelli, L. A2Aadenosine receptor reserve for coronary vasodilation. Circulation, 1998, 98, 711-718.
34. Dobson, J. G.,Jr; Fenton, R. A. Adenosine A2 receptor function in rat ventricular myocytes. Cardiovasc. Res., 1997, 34, 337-347.
35. Mizuno, M.; Kimura, Y.; Tokizawa, K.; Ishii, K.; Oda, K.; Sasaki, T.; Nakamura, Y.; Muraoka, I.; Ishiwata, K. Greater adenosine A2A receptor densities in cardiac and skeletal muscle in endurance- trained men: a [11C]TMSX PET study. Nucl. Med. Biol., 2005, 32, 831-836.
36. Bauer, A.; Ishiwata, K. Adenosine Receptor Ligands and PET Imaging of the CNS. Handb. Exp. Pharmacol., 2009, 193, 617-642.
37. Holschbach, M. H.; Olsson, R. A. Applications of adenosine receptor ligands in medical imaging by positron emission tomography. Curr. Pharm. Des., 2002, 8, 2345-2352.
38. Brooks, D. J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J. Neurol., 2000, 247, II11-II18.
39. Ishiwata, K.; Kawamura, K.; Kimura, Y.; Oda, K.; Ishii, K. Potential of an adenosine A2A receptor antagonist [11C]TMSX for myocardial imaging by positron emission tomography: a first human study. Ann. Nucl. Med., 2003, 17, 457-462.
40. Ishiwata, K.; Mizuno, M.; Kimura, Y.; Kawamura, K.; Oda, K.; Sasaki, T.; Nakamura, Y.; Muraoka, I.; Ishii, K. Potential of [11C]TMSX for the evaluation of adenosine A2A receptors in the skeletal muscle by positron emission tomography. Nucl. Med. Biol., 2004, 31, 949-956.
41. Heinonen, I.; Nesterov, S. V.; Liukko, K.; Kemppainen, J.; Någren, K.; Luotolahti, M.; Virsu, P.; Oikonen, V.; Nuutila, P.; Kujala, U. M.; Kainulainen, H.; Boushel, R.; Knuuti, J.; Kalliokoski, K. K. Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men. J. Physiol., 2008, 586, 5193-5202.
42. Mishina, M.; Kimura, Y.; Naganawa, M.; Ishii, K.; Oda, K.; Sakata, M.; Toyohara, J.; Kobayashi, S.; Katayama, Y.; Ishiwata, K. Differential effects of age on human striatal adenosine A(1) and A(2A) receptors. Synapse, 2012, 66, 832-839.
43. Mishina, M.; Ishiwata, K.; Kimura, Y.; Naganawa, M.; Oda, K.; Kobayashi, S.; Katayama, Y.; Ishii, K. Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET. Synapse, 2007, 61, 778-784.
44. Naganawa, M.; Kimura, Y.; Mishina, M.; Manabe, Y.; Chihara, K.; Oda, K.; Ishii, K.; Ishiwata, K. Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 679-687.
45. Mishina, M.; Ishiwata, K.; Naganawa, M.; Kimura, Y.; Kitamura, S.; Suzuki, M.; Hashimoto, M.; Ishibashi, K.; Oda, K.; Sakata, M.; Hamamoto, M.; Kobayashi, S.; Katayama, Y.; Ishii, K. Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients. PLoS One, 2011, 6, e17338.
46. Brooks, D. J.; Doder, M.; Osman, S.; Luthra, S. K.; Hirani, E.; Hume, S.; Kase, H.; Kilborn, J.; Martindill, S.; Mori, A. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse, 2008, 62, 671-681.
47. Matsuya, T.; Takuma, K.; Sato, K.; Asai, M.; Murakami, Y.; Miyoshi, S.; Noda, A.; Nagai, T.; Mizoguchi, H.; Nishimura, S.; Yamada, K. Synergistic effects of adenosine A2A antagonist and LDOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. J. Pharmacol. Sci., 2007, 103, 329-332.
48. Bhattacharjee, A. K.; Lang, L.; Jacobson, O.; Shinkre, B.; Ma, Y.; Niu, G.; Trenkle, W. C.; Jacobson, K. A.; Chen, X.; Kiesewetter, D. O. Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425. Nucl. Med. Biol., 2011, 38, 897-906.
49. Ramlackhansingh, A. F.; Bose, S. K.; Ahmed, I.; Turkheimer, F. E.; Pavese, N.; Brooks, D. J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology, 2011, 76, 1811-1816.
50. Brooks, D. J.; Papapetropoulos, S.; Vandenhende, F.; Tomic, D.; He, P.; Coppell, A.; O'Neill, G. An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin. Neuropharmacol., 2010, 33, 55-60.
51. Burnstock, G. Purinergic signalling and disorders of the central nervous system. Nat. Rev. Drug Discov., 2008, 7, 575-590.
52. Baraldi, P. G.; Tabrizi, M. A.; Gessi, S.; Borea, P. A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev., 2008, 108, 238-263.
53. Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2005, 105, 267-310.
54. Hauser, R. A.; Schwarzschild, M. A. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging, 2005, 22, 471-482.
55. Okusa, M. D. A(2A) adenosine receptor: a novel therapeutic target in renal disease. Am. J. Physiol. Renal Physiol., 2002, 282, F10-F18.
56. Pinna, A.; Wardas, J.; Simola, N.; Morelli, M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci., 2005, 77, 3259-3267.
57. Pinna, A. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin. Investig. Drugs, 2009, 18, 1619-1631.
58. Press, N. J.; Gessi, S.; Borea, P. A.; Polosa, R. Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin. Ther. Pat., 2007, 17, 979-991.
59. Cristalli, G.; Cacciari, B.; Dal Ben, D.; Lambertucci, C.; Moro, S.; Spalluto, G.; Volpini, R. Highlights on the development of A(2A) adenosine receptor agonists and antagonists. ChemMedChem, 2007, 2, 260-281.
60. Ishiwata, K.; Noguchi, J.; Toyama, H.; Sakiyama, Y.; Koike, N.; Ishii, S.; Oda, K.; Endo, K.; Suzuki, F.; Senda, M. Synthesis and preliminary evaluation of [11C]KF17837, a selective adenosine A2A antagonist. Appl. Radiat. Isot., 1996, 47, 507-511.
61. Ishiwata, K.; Noguchi, J.; Wakabayashi, S.; Shimada, J.; Ogi, N.; Nariai, T.; Tanaka, A.; Endo, K.; Suzuki, F.; Senda, M. 11Clabeled KF18446: a potential central nervous system adenosine A2a receptor ligand. J. Nucl. Med., 2000, 41, 345-354.
62. Stone-Elander, S.; Thorell, J.; Eriksson, L.; Fredholm, B. B.; Ingvar, M. In vivo biodistribution of [N-11C-methyl]KF 17837 using 3-D-PET: Evaluation as a ligand for the study of adenosine A2A receptors. Nucl. Med. Biol., 1997, 24, 187-191.
63. Marian, T.; Boros, I.; Lengyel, Z.; Balkay, L.; Horvath, G.; Emri, M.; Sarkadi, E.; Szentmiklosi, A. J.; Fekete, I.; Tron, L. Preparation and primary evaluation of [11C]CSC as a possible tracer for mapping adenosine A2A receptors by PET. Appl. Radiat. Isot., 1999, 50, 887-893.
64. Hirani, E.; Gillies, J.; Karasawa, A.; Shimada, J.; Kase, H.; Opacka-Juffry, J.; Osman, S.; Luthra, S. K.; Hume, S. P.; Brooks, D. J. Evaluation of [4-O-methyl-(11)C]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats. Synapse, 2001, 42, 164-176.
65. Kawamura, K.; Ishiwata, K. Improved synthesis of [11C]SA4503, [11C]MPDX and [11C]TMSX by use of [11C]methyl triflate. Ann. Nucl. Med., 2004, 18, 165-168.
66. Wang, W.; Ishiwata, K.; Nonaka, H.; Ishii, S.; Kiyosawa, M.; Shimada, J.; Suzuki, F.; Senda, M. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A2A receptors with positron emission tomography. Nucl. Med. Biol., 2000, 27, 541-546.
67. Jacobson, K. A.; Gallo-Rodriguez, C.; Melman, N.; Fischer, B.; Maillard, M.; van Bergen, A.; van Galen, P. J.; Karton, Y. Structure- activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J. Med. Chem., 1993, 36, 1333-1342.
68. Nonaka, Y.; Shimada, J.; Nonaka, H.; Koike, N.; Aoki, N.; Kobayashi, H.; Kase, H.; Yamaguchi, K.; Suzuki, F. Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3- Dipropyl-8-(3,4-dimethoxystyryl)-7- methylxanthine. J. Med. Chem., 1993, 36, 3731-3733.
69. Nonaka, H.; Ichimura, M.; Takeda, M.; Nonaka, Y.; Shimada, J.; Suzuki, F.; Yamaguchi, K.; Kase, H. KF17837 ((E)-8-(3,4- dimethoxystyryl)-1,3-dipropyl- 7-methylxanthine) a potent and selective adenosine A2 receptor antagonist. Eur. J. Pharmacol., 1994, 267, 335-341.
70. Shimada, J.; Suzuki, F.; Nonaka, H.; Ishii, A.; Ichikawa, S. (E)-1,3- Dialkyl-7-methyl-8-(3,4,5-trimethoxy-styryl)xanthines: Potent and selective adenosine A2 antagonists. J. Med. Chem., 1992, 35, 2342-2345.
71. Ishiwata, K.; Sakiyama, Y.; Sakiyama, T.; Shimada, J.; Toyama, H.; Oda, K.; Suzuki, F.; Senda, M. Myocardial adenosine A2a receptor imaging of rabbit by PET with [11C]KF17837. Ann. Nucl. Med., 1997, 11, 219-225.
72. Noguchi, J.; Ishiwata, K.; Wakabayashi, S.; Nariai, T.; Shumiya, S.; Ishii, S.; Toyama, H.; Endo, K.; Suzuki, F.; Senda, M. Evaluation of carbon-11-labeled KF17837: a potential CNS adenosine A2a receptor ligand. J. Nucl. Med., 1998, 39, 498-503.
73. Cunha, R. A.; Johansson, B.; Constantino, M. D.; Sebastiao, A. M.; Fredholm, B. B. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Naunyn Schmiedebergs Arch. Pharmacol., 1996, 353, 261-271.
74. Parkinson, F. E.; Fredholm, B. B. Autoradiographic evidence for G-protein coupled A2-receptors in rat neostriatum using [3H]-CGS 21680 as a ligand. Naunyn Schmiedebergs Arch. Pharmacol., 1990, 342, 85-89.
75. Martinez-Mir, M. I.; Probst, A.; Palacios, J. M. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience, 1991, 42, 697-706.
76. Fastbom, J.; Pazos, A.; Palacios, J. M. The distribution of adenosine a1 receptors and 5'-nucleotidase in the brain of some commonly used experimental animals. Neuroscience, 1987, 22, 813-826.
77. Ishiwata, K.; Shimada, J.; Wang, W. F.; Harakawa, H.; Ishii, S.; Kiyosawa, M.; Suzuki, F.; Senda, M. Evaluation of iodinated and brominated [11C]styrylxanthine derivatives as in vivo radioligands mapping adenosine A2A receptor in the central nervous system. Ann. Nucl. Med., 2000, 14, 247-253.
78. Ishiwata, K.; Ogi, N.; Shimada, J.; Nonaka, H.; Tanaka, A.; Suzuki, F.; Senda, M. Further characterization of a CNS adenosine A2a receptor ligand [11C] KF18446 with in vitro autoradiography and in vivo tissue uptake. Ann. Nucl. Med., 2000, 14, 81-89.
79. Ishiwata, K.; Ogi, N.; Shimada, J.; Wang, W.; Ishii, K.; Tanaka, A.; Suzuki, F.; Senda, M. Search for PET probes for imaging the globus pallidus studied with rat brainex vivo autoradiography. Ann. Nucl. Med., 2000, 14, 461-466.
80. Ishiwata, K.; Wang, W. F.; Kimura, Y.; Kawamura, K.; Ishii, K. Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography. Ann. Nucl. Med., 2003, 17, 205-211.
81. Todde, S.; Moresco, R. M.; Simonelli, P.; Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Varani, K.; Monopoli, A.; Matarrese, M.; Carpinelli, A.; Magni, F.; Kienle, M. G.; Fazio, F. Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. J. Med. Chem., 2000, 43, 4359-4362.
82. Shinkre, B. A.; Kumar, T. S.; Gao, Z. G.; Deflorian, F.; Jacobson, K. A.; Trenkle, W. C. Synthesis and evaluation of 1,2,4- triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 5690-5694.
83. Kumar, T. S.; Mishra, S.; Deflorian, F.; Yoo, L. S.; Phan, K.; Kecskes, M.; Szabo, A.; Shinkre, B.; Gao, Z. G.; Trenkle, W.; Jacobson, K. A. Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4] triazolo[1,5-c]pyrimidin-5-amine scaffold. Bioorg. Med. Chem. Lett., 2011, 21, 2740-2745.
84. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Monopoli, A.; Ongini, E.; Varani, K.; Borea, P. A. 7-Substituted 5- amino-2-(2-furyl) pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J. Med. Chem., 2002, 45, 115-126.
85. Moresco, R. M.; Todde, S.; Belloli, S.; Simonelli, P.; Panzacchi, A.; Rigamonti, M.; Galli-Kienle, M.; Fazio, F. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 405-413.
86. Calon, F.; Dridi, M.; Hornykiewicz, O.; Bedard, P. J.; Rajput, A. H.; Di Paolo, T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain, 2004, 127, 1075-1084.
87. Mihara, T.; Noda, A.; Arai, H.; Mihara, K.; Iwashita, A.; Murakami, Y.; Matsuya, T.; Miyoshi, S.; Nishimura, S.; Matsuoka, N. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. J. Nucl. Med., 2008, 49, 1183-1188.
88. Morelli, M.; Blandini, F.; Simola, N.; Hauser, R. A. A2A Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinson's Disease, 2012, 2012, 8.
89. Daly, J. W.; Hide, I.; Muller, C. E.; Shamim, M. Caffeine Analogs: Structure-Activity Relationships at Adenosine Receptors. Pharmacology, 1991, 42, 309-321.
90. Muller, C. E.; Geis, U.; Hipp, J.; Schobert, U.; Frobenius, W.; Pawlowski, M.; Suzuki, F.; Sandoval-Ramirez, J. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. J. Med. Chem., 1997, 40, 4396-4405.
91. Muller, C. E.; Sandoval-Ramirez, J.; Schobert, U.; Geis, U.; Frobenius, W.; Klotz, K. N. 8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. Bioorg. Med. Chem., 1998, 6, 707-719.
92. Muller, C. E.; Ferre, S. Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent. Pat. CNS Drug Discov., 2007, 2, 1-21.
93. Cristalli, G.; Muller, C. E.; Volpini, R. Recent developments in adenosine A2A receptor ligands. Handb. Exp. Pharmacol., 2009, 193, 59-98.
94. Drabczynska, A.; Schumacher, B.; Muller, C. E.; Karolak-Wojciechowska, J.; Michalak, B.; Pekala, E.; Kiec-Kononowicz, K. Impact of the aryl substituent kind and distance from pyrimido[2,1- f]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur. J. Med. Chem., 2003, 38, 397-402.
95. Weyler, S.; Fulle, F.; Diekmann, M.; Schumacher, B.; Hinz, S.; Klotz, K. N.; Muller, C. E. Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem, 2006, 1, 891-902.
96. Muller, C. E. Medicinal chemistry of adenosine A3 receptor ligands. Curr. Top. Med. Chem., 2003, 3, 445-462.
97. Bulicz, J.; Bertarelli, D. C.; Baumert, D.; Fulle, F.; Muller, C. E.; Heber, D. Synthesis and pharmacology of pyrido[2,3- d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists. Bioorg. Med. Chem., 2006, 14, 2837-2849.
98. Minetti, P.; Tinti, M. O.; Carminati, P.; Castorina, M.; Di Cesare, M. A.; Di Serio, S.; Gallo, G.; Ghirardi, O.; Giorgi, F.; Giorgi, L.; Piersanti, G.; Bartoccini, F.; Tarzia, G. 2-n-Butyl-9-methyl-8- [1,2,3]triazol-2-yl-9H- purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J. Med. Chem., 2005, 48, 6887-6896.
99. Gatta, F.; Del Giudice, M.; Borioni, A.; Borea, P.; Dionisotti, S.; Ongini, E. Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo [5,1-i]purines: new potent adenosine A2 receptor antagonists. Eur. J. Med. Chem., 1993, 28, 569-576.
100. Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Bergonzoni, M.; Dionisotti, S.; Ongini, E.; Varani, K.; Borea, P. A. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]- 1,2,4-triazolo[1,5-c] pyrimidines as potent and selective A2A adenosine receptor antagonists. J. Med. Chem., 1998, 41, 2126-2133.
101. Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Pineda de las Infantas y Villatoro,M.J.; Zocchi, C.; Dionisotti, S.; Ongini, E. Pyrazolo[4,3- e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists. J. Med. Chem., 1996, 39, 1164-1171.
102. Neustadt, B. R.; Hao, J.; Lindo, N.; Greenlee, W. J.; Stamford, A. W.; Tulshian, D.; Ongini, E.; Hunter, J.; Monopoli, A.; Bertorelli, R.; Foster, C.; Arik, L.; Lachowicz, J.; Ng, K.; Feng, K. Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidines. Bioorg. Med. Chem. Lett., 2007, 17, 1376-1380.
103. Silverman, L. S.; Caldwell, J. P.; Greenlee, W. J.; Kiselgof, E.; Matasi, J. J.; Tulshian, D. B.; Arik, L.; Foster, C.; Bertorelli, R.; Monopoli, A.; Ongini, E. 3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 1659-1662.
104. Holschbach, M. H.; Bier, D.; Wutz, W.; Sihver, W.; Schuller, M.; Olsson, R. A. Derivatives of 4,6-diamino-1,2-dihydro-2-phenyl- 1,2,4-triazolo[4,3-a] quinoxalin-2H-1-one: potential antagonist ligands for imaging the A2A adenosine receptor by positron emission tomography (PET). Eur. J. Med. Chem., 2005, 40, 421-437.
105. Holschbach, M. H.; Bier, D.; Stusgen, S.; Wutz, W.; Sihver, W.; Coenen, H. H.; Olsson, R. A. Synthesis and evaluation of 7-amino- 2-(2(3)-furyl)-5- phenylethylamino-oxazolo [5,4-d]pyrimidines as potential A2A adenosine receptor antagonists for positron emission tomography (PET). Eur. J. Med. Chem., 2006, 41, 7-15.
106. Matasi, J. J.; Caldwell, J. P.; Hao, J.; Neustadt, B.; Arik, L.; Foster, C. J.; Lachowicz, J.; Tulshian, D. B. The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 1333-1336.
107. Vu, C. B.; Pan, D.; Peng, B.; Sha, L.; Kumaravel, G.; Jin, X.; Phadke, D.; Engber, T.; Huang, C.; Reilly, J.; Tam, S.; Petter, R. C. Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles. Bioorg. Med. Chem. Lett., 2004, 14, 4831-4834.
108. Dowling, J. E.; Vessels, J. T.; Haque, S.; Chang, H. X.; van Vloten, K.; Kumaravel, G.; Engber, T.; Jin, X.; Phadke, D.; Wang, J.; Ayyub, E.; Petter, R. C. Synthesis of [1,2,4]triazolo[1,5- a]pyrazines as adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 4809-4813.
109. Matasi, J. J.; Caldwell, J. P.; Zhang, H.; Fawzi, A.; Cohen-Williams, M. E.; Varty, G. B.; Tulshian, D. B. 2-(2-Furanyl)-7- phenyl[1,2,4]triazolo[1,5-c] pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1. Bioorg. Med. Chem. Lett., 2005, 15, 3670-3674.
110. Matasi, J. J.; Caldwell, J. P.; Zhang, H.; Fawzi, A.; Higgins, G. A.; Cohen-Williams, M. E.; Varty, G. B.; Tulshian, D. B. 2-(2- Furanyl)-7-phenyl[1, 2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2. Bioorg. Med. Chem. Lett., 2005, 15, 3675-3678.
111. Vu, C. B.; Peng, B.; Kumaravel, G.; Smits, G.; Jin, X.; Phadke, D.; Engber, T.; Huang, C.; Reilly, J.; Tam, S.; Grant, D.; Hetu, G.; Chen, L.; Zhang, J.; Petter, R. C. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5] triazine as potent and selective adenosine A2a receptor antagonists. J. Med. Chem., 2004, 47, 4291-4299.
112. Vu, C. B.; Pan, D.; Peng, B.; Kumaravel, G.; Smits, G.; Jin, X.; Phadke, D.; Engber, T.; Huang, C.; Reilly, J.; Tam, S.; Grant, D.; Hetu, G.; Petter, R. C. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists. J. Med. Chem., 2005, 48, 2009-2018.
113. Peng, H.; Kumaravel, G.; Yao, G.; Sha, L.; Wang, J.; Van Vlijmen, H.; Bohnert, T.; Huang, C.; Vu, C. B.; Ensinger, C. L.; Chang, H.; Engber, T. M.; Whalley, E. T.; Petter, R. C. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. J. Med. Chem., 2004, 47, 6218-6229.
114. Vu, C. B.; Shields, P.; Peng, B.; Kumaravel, G.; Jin, X.; Phadke, D.; Wang, J.; Engber, T.; Ayyub, E.; Petter, R. C. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 4835-4838.
115. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322, 1211-1217.
116. Ye, Y.; Wei, J.; Dai, X.; Gao, Q. Computational studies of the binding modes of A 2A adenosine receptor antagonists. Amino Acids, 2008, 35, 389-396.
117. Kim, J.; Wess, J.; van Rhee, A. M.; Schoneberg, T.; Jacobson, K. A. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J. Biol. Chem., 1995, 270, 13987-13997.
118. Neustadt, B. R.; Liu, H.; Hao, J.; Greenlee, W. J.; Stamford, A. W.; Foster, C.; Arik, L.; Lachowicz, J.; Zhang, H.; Bertorelli, R.; Fredduzzi, S.; Varty, G.; Cohen-Williams, M.; Ng, K. Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5- c]pyrimidines. Bioorg. Med. Chem. Lett., 2009, 19, 967-971.